Abilify® (aripiprazole) is a prescription drug used to treat mental illnesses such as depression, bipolar disorder, schizophrenia, and Tourette syndrome. Recent reports have linked the drug with compulsive behavior in patients, including pathological gambling and hypersexual activity.
Approved by the U.S. Food and Drug Administration (FDA) in 2002, Abilify is a top-selling drug raking in billions of dollars each year for its manufacturers. But reports link Abilify to compulsive behaviors, and European and Canadian regulatory agencies have required drug manufacturers to add new warnings to drug packaging about the increased risks.
Abilify® and Pathological Gambling
Abilify treats mental illnesses by targeting levels of dopamine and serotonin in the brain, which produce feelings of pleasure and motivation. However, a report published by the British Journal of Psychology suggests Abilify may over-stimulate the reward system in patients’ brains, causing them to develop an impulse control disorder.
Pathological gambling has been reported in patients taking Abilify to treat mental illness, regardless of whether these patients had prior history of gambling. Compulsive gambling can have adverse effects on patients and their loved ones, including:
- Personal debt
- Emotional trauma
- Home foreclosure
- Damaged reputation
FDA Warns of Abilify® Link to Impulse Control Problems
In May 2016, the FDA issued a drug safety communication stating that Abilify warning labels will be updated to include the potential risk of compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex.
According to the FDA, most patients who experience Abilify impulse control problems have no history of compulsive behavior before taking the drug, and uncontrollable urges usually stop within days or weeks of reducing Abilify dosage or discontinuing its use.
Get Help With Your Abilify® Lawsuit
If you or someone you love has developed a compulsive gambling habit after taking Abilify, you may be entitled to compensation. Contact a drug injury lawyer at Cory Watson Attorneys to get the help you deserve. Give us a call at (877) 562-0000 or fill out our free initial consultation form.
Abilify® is a registered trademark of Bristol-Myers Squibb and Otsuka America Pharmaceutical, and is used here only to identify the product in question.
This law firm is not associated with, sponsored by, or affiliated with Bristol-Myers Squibb Company; The British Journal of Psychology; Otsuka Pharmaceutical Co., Ltd.; or the U.S. Food and Drug Administration.